Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr
News

Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr

Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023

  • By IPP Bureau | January 23, 2024

Glenmark Life Sciences Ltd has reported Standalone financial results for the period ended December 31, 2023.

Glenmark Life Sciences has posted net profit of Rs. 118.76 crores for the period ended December 31, 2023 as against net profit of Rs. 118.73 crores for the period ended September 30, 2023. The company posted net profit of Rs.104.993 crores for the period ended December 31, 2022.

Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023 as compared to Rs. 600.73 crores during the period ended September 30, 2023. The company reported total income of Rs.547.339 crores during the period ended December 31, 2022.

For the 9 months period ended December 31, 2023, Glenmark Life Sciences has reported total income of Rs.1755.528 crores as compared to Rs.1566.021 crores during the 9 months period ended December 31, 2022.

The company has posted net profit of Rs.372.952 crores for the 9 months period ended December 31, 2023 as against net profit of Rs.320.604 crores for the 9 months period ended December 31, 2022.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International